SEMA3A and glioblastoma: The availability of BA‐induced oxidative stress and SEMA3A biomarkers in a dose‐dependent manner, the mechanism of apoptosis, and the effective dose of BA can be evaluated for the focus of future pre‐clinical studies on glioblastoma.